Remedor Biomed Ltd Report issue

For profit Phase 2
Founded: Nazareth Israel (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2015
NCT02361931
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

aluminum hydroxide (Gaviscon) (1 trial)

epoetin (Epogen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2